The data underlying the results presented in this study are available by request from the Scientific Registry of Transplant Recipients at: <https://www.srtr.org/requesting-srtr-data/data-requests/> The Scientific Registry of Transplant Recipients is a 3rd party. The authors do not have special privileges so others are able to access the data in the same manner.

Introduction {#sec005}
============

In 2016, nearly 100,000 patients were listed on the United States (US) deceased donor kidney transplant waitlist, and 20% of these patients had been waiting for at least six years \[[@pone.0233610.ref001]\]. These stark figures reflect an ongoing shortage of donor kidneys and fuel interest in both expanding the pool of potential donors and optimizing the use of available kidneys \[[@pone.0233610.ref002]\]. The majority of deceased donor kidneys come from donors after brain death (DBD) who have died by neurologic criteria. However, since their introduction in 1993, donors after circulatory death (DCD) make up a growing proportion of all deceased donor kidneys. DCD kidneys comprised 2% of deceased donor kidney transplants in 2000, 8% by 2005, and 20% by 2017 \[[@pone.0233610.ref003]\]. Use of DCD kidneys has also expanded among European transplant programs after the practice was approved by the World Health Organization in 2011, but attitudes, policies, and practices vary geographically \[[@pone.0233610.ref004]\]. Of 35 European countries participating in a recent survey, 18 reported active DCD programs and 9 additional countries reported interest in developing these programs \[[@pone.0233610.ref005]\].

In the US, the vast majority of DCD kidneys are obtained after a donor has died as defined by absence of cardiopulmonary circulation after withdrawal of life-supporting treatment (Maastricht category III) \[[@pone.0233610.ref006],[@pone.0233610.ref007]\]. Transplant centers typically wait for a maximum of one hour after withdrawal of life supporting treatment and are required to observe a two to five-minute waiting period after cessation of cardiorespiratory function before death is declared \[[@pone.0233610.ref008]\]. During this waiting period, the donor can have systemic hypotension \[[@pone.0233610.ref008]\], which may cause ischemic kidney injury and likely contributes to the delayed graft function after transplant that occurs for 50--60% of DCD recipients \[[@pone.0233610.ref009]--[@pone.0233610.ref011]\]. DCD kidneys have also been associated with longer hospital length of stay, readmissions, acute rejection, and more frequent graft loss compared with DBD kidneys \[[@pone.0233610.ref010],[@pone.0233610.ref012]--[@pone.0233610.ref014]\]. However, multiple recent studies suggest that despite a higher risk of delayed graft function \[[@pone.0233610.ref015],[@pone.0233610.ref016]\], DCD kidneys may offer comparable recipient outcomes compared with DBD kidneys \[[@pone.0233610.ref001],[@pone.0233610.ref011],[@pone.0233610.ref017],[@pone.0233610.ref018]\]. Nevertheless, DCD kidneys continue to be considered lower quality than DBD kidneys in the US and Europe \[[@pone.0233610.ref005]\] and are discarded at much higher rates than other deceased donor kidneys \[[@pone.0233610.ref001],[@pone.0233610.ref019]--[@pone.0233610.ref021]\]. DCD status was determined to be predictive of poorer graft survival as a component of the kidney donor risk index (KDRI) by Rao et al. in a cohort of patients who received a kidney transplant from 1995 to 2005 and the relevance of this factor was reaffirmed by Zhong et al. in a cohort of patients who received a kidney transplant from 2000--2016 \[[@pone.0233610.ref022],[@pone.0233610.ref023]\]. This index measure of kidney quality has become an integral component of organ-matching and selection for the national kidney allocation system.

The association between donor kidney DCD status and recipient outcomes remains unclear. In this study, we compare rates of graft loss between DCD and DBD kidneys for a contemporary cohort of deceased donor kidney transplant recipients.

Patients and methods {#sec006}
====================

Study population and data source {#sec007}
--------------------------------

We conducted a retrospective analysis of all adult kidney transplant recipients who underwent their first single-organ deceased donor kidney transplant from 12/4/2014 to 6/30/2018 in the United States. We used a dataset that was released by the Organ Procurement and Transplantation Network (OPTN) on 12/01/2018 and included data collected by the United Network for Organ Sharing (UNOS) through 9/30/2018. Recipients were excluded if they were younger than 18 years old, if they received simultaneous organ transplants, or if they received a repeat kidney transplant. For a secondary analysis, we created a comparator cohort of patients who received a deceased donor kidney transplant from 1/1/1995-12/3/2014 with the same exclusion criteria. The OPTN database is de-identified and publicly available; therefore, this study was exempt from human subject review as approved by the University of Washington Human Subjects Division.

Using UNOS donor data, we stratified cohort members into two groups based on whether they received a DCD or DBD kidney. We also collected data representing the annual number of DCD transplants performed in the US from 1995 to 2018, and the proportion of programs performing at least one DCD transplant per year.

Covariates {#sec008}
----------

Using data reported on UNOS transplant recipient forms, we determined donor age, sex, race or ethnicity (Asian, black, Hispanic, white, other), height, weight, cause of death (anoxia, cerebral vascular accident (CVA), head trauma, or other cause), serum creatinine, hepatitis C virus (HCV) positivity (by serology or NAT positivity) and history of diabetes mellitus (DM), hypertension, and cigarette smoking. We further determined recipient age, sex, race or ethnicity, height, weight, panel reactive antigen result (PRA), history of end-stage kidney disease (ESKD) prior to transplant, peripheral vascular disease, and malignancy, HCV and Epstein-Barr Virus (EBV) positivity, time spent on the waitlist, and primary cause of kidney disease (cancer, congenital kidney disease, diabetes mellitus, medication, glomerulonephritis, hypertension, metabolic disease, interstitial nephritis, polycystic kidney disease, systemic lupus erythematous, anatomic abnormality, or other cause). We also determined whether the donor graft was preserved by machine perfusion before transplantation, the graft cold ischemia time (CIT), and whether the graft was transplanted en-bloc (a technique in which two kidneys are transplanted together as one graft). We ascertained whether the donation occurred through organ sharing at the local, regional, or national level and the degree of HLA-DR and HLA-B antigen mismatching between donor and recipient. These factors were chosen to represent all currently available variables that were included in the foundational publication by Rao et al. that described characteristics associated with deceased donor graft function. \[[@pone.0233610.ref022]\] For a supplementary descriptive analysis, we ascertained the kidney donor profile index (KDPI) recorded for each deceased donor kidney.

There were 208 missing values for donor diabetes mellitus status, 258 missing values for donor hypertension status, 563 missing values for donor smoking status, and 7 missing values reporting whether the donor kidney was preserved by machine perfusion. All these missing values were recorded as unknown and entered into the analysis. 254 missing values for CIT were imputed by linear regression using distance, type of sharing, and region of transplant.

Outcomes {#sec009}
--------

We collected data for all recipients until 9/30/2018, which included 90 days beyond the end of study follow-up to account for late filing of UNOS transplant recipient forms. Our primary outcome of interest was all-cause graft loss (including graft loss secondary to recipient death) and secondary outcome was death-censored graft loss.

As a supplementary descriptive analysis, we used a modified version of the KDRI score that we calculated after excluding the coefficient for DCD status. \[[@pone.0233610.ref024]\] We then used KDRI-to-KDPI mapping tables applicable to each year of transplant to approximate KDPI values. We compared this modified KDPI score with the KDPI reported by UNOS for DCD grafts received by cohort members.

Statistical analysis {#sec010}
--------------------

We used median and interquartile ranges (IQR) and Student's t-tests or Kruskal-Wallis tests, as appropriate for each distribution, for continuous variables and percentages and chi-square tests for categorical variables to describe and compare donor and recipient characteristics between groups defined by DCD versus DBD status ([Table 1](#pone.0233610.t001){ref-type="table"}).

10.1371/journal.pone.0233610.t001

###### Cohort characteristics.

![](pone.0233610.t001){#pone.0233610.t001g}

                                                                Deceased donor graft type                       
  ------------------------------------------------------------- --------------------------- ------------------- ---------
  Age groups, %                                                                                                  
      0--17 y                                                   9.1                         7.8                 \<0.001
      18--30 y                                                  25.1                        23.6                0.005
      31--45 y                                                  28.9                        30.0                0.06
      46--65 y                                                  34.1                        38.6                \<0.001
      \>65 y                                                    2.8                         0.1                 \<0.001
  Female, %                                                     40.5                        34.3                \<0.001
  Race, %                                                                                                        
      Asian                                                     2.6                         1.9                 \<0.001
      Black                                                     15.4                        8.0                 \<0.001
      Hispanic                                                  14.9                        9.8                 \<0.001
      White                                                     64.8                        79.1                \<0.001
      Other                                                     2.3                         1.2                 \<0.001
  Height groups, %                                                                                               
      \<80 cm                                                   1.0                         1.0                 0.61
      80 to 170 cm                                              47.6                        40.8                \<0.001
      \>170 cm                                                  51.4                        58.3                \<0.001
  Weight groups, %                                                                                               
      \<30 kg                                                   4.2                         2.7                 \<0.001
      30 to 80 kg                                               47.5                        43.9                \<0.001
      \>80 to 110 kg                                            37.8                        40.5                \<0.001
      \>110 kg                                                  10.5                        13.0                \<0.001
  Cause of death, %                                                                                              
      Anoxia                                                    38.1                        51.4                \<0.001
      CVA                                                       27.9                        16.4                \<0.001
      Head Trauma                                               31.2                        27.4                \<0.001
      Other                                                     2.8                         4.9                 \<0.001
  Serum Creatinine (mg/dL), median (IQR)                        1.0 (0.7--1.5)              0.8 (0.6--1.1)      \<0.001
  HCV status positive[\*](#t001fn001){ref-type="table-fn"}, %   4.8                         2.2                 \<0.001
  Diabetes, %                                                   7.7                         6.0                 \<0.001
  Hypertension, %                                               29.0                        26.7                \<0.001
  Cigarette Smoking, %                                          18.7                        19.8                0.03
  **Recipient characteristics**                                                                                  
  Age, years (IQ)                                               55 (43--63)                 56 (46--64)         \<0.001
  Female, %                                                     40.9                        39.2                0.006
  Race, %                                                                                                        
      Asian                                                     7.4                         7.5                 0.83
      Black                                                     37.1                        32.4                \<0.001
      Hispanic                                                  19.8                        18.9                0.07
      White                                                     33.2                        38.1                \<0.001
      Other                                                     2.4                         3.1                 \<0.001
  Height groups, %                                                                                               
      \<163 cm                                                  24.4                        24.1                0.50
      163--178 cm                                               55.3                        54.4                0.17
      \>178                                                     20.3                        21.5                0.02
  Weight groups, %                                                                                               
      \<70 kg                                                   28.3                        26.0                \<0.001
      70--85 kg                                                 31.4                        31.3                0.88
      \>85--100 kg                                              23.2                        24.6                0.01
      \>100 kg                                                  17.1                        18.1                0.04
  Panel reactive antibody level                                                                                 
      0--10                                                     68.8                        71.0                \<0.001
      11--100                                                   31.2                        29.0                \<0.001
  End stage kidney disease                                      88.3                        87.8                0.16
  Peripheral vascular disease                                   8.8                         9.2                 0.36
  History of malignancy                                         8.1                         7.7                 0.25
  HCV Positive                                                  6.1                         4.3                 \<0.001
  EBV Positive                                                  87.4                        87.5                0.77
  Time on waiting on list, days (IQR)                           698 (194--1433)             692 (191--1416)     0.20
  Primary cause of kidney disease                                                                               
      Cancer                                                    0.5                         0.6                 0.63
      Congenital                                                1.2                         1.2                 0.87
      Diabetes Mellitus                                         30.8                        33.4                \<0.001
      Medication                                                0.3                         0.2                 0.05
      Glomerulonephritis                                        10.6                        10.6                0.86
      Hypertension                                              28.3                        25.8                \<0.001
      Metabolic disease                                         1.2                         1.3                 0.42
      Interstitial nephritis                                    6.3                         6.9                 0.05
      Polycystic kidney disease                                 7.9                         8.1                 0.59
      Systemic lupus erythematous                               3.5                         2.9                 0.01
      Anatomic abnormality                                      1.2                         1.1                 0.47
      Other                                                     8.2                         8.1                 0.86
  **Transplant logistics**                                                                                       
  Kidney graft placed on machine perfusion                      29.8                        51.8                \<0.001
  Cold ischemia time, hrs, median (IQR)                         16.2 (11.0--22.3)           18.7 (14.0--23.5)   \<0.001
  En-bloc kidney graft                                          1.9                         1.6                 0.03
  Sharing network, %                                                                                             
      Local                                                     72.0                        76.5                \<0.001
      Regional                                                  13.2                        11.2                \<0.001
      National                                                  14.8                        12.3                \<0.001
  Number of B-antigen mismatches, %                                                                              
      0                                                         6.4                         6.2                 0.54
      1                                                         24.5                        25.4                0.09
      2                                                         69.2                        68.4                0.21
  Number of DR-antigen mismatches, %                                                                             
      0                                                         14.7                        15.5                0.09
      1                                                         48.4                        49.3                0.17
      2                                                         36.8                        35.2                0.01

\* by serology or NAT positivity.

P-value by Student's t-tests, Kruskal-Wallis tests, or chi-squared as appropriate.

To determine the unadjusted and adjusted hazard ratio of graft loss associated with DCD status, we used univariable and multivariable Cox proportional hazards models with mixed effects. This model allowed us to account for cluster-specific random effects that result in differing baseline hazard functions between transplant centers \[[@pone.0233610.ref025]\]. For the multivariable analysis, we controlled for all measured donor characteristics (age, sex, race or ethnicity, height, weight, cause of death, serum creatinine, HCV status, history of DM, hypertension and smoking), recipient characteristics (age, sex, race or ethnicity, height, weight, PRA, history of ESKD, peripheral vascular disease, and malignancy, HCV and EBV positivity, time spent on the waitlist, and primary cause of kidney disease), and all measured aspects of transplant logistics (whether the graft was preserved by mechanical perfusion, CIT, whether the graft was transplanted en-bloc, sharing network \[i.e., local, regional, national\], and B- and DR-antigen mismatches).

In a supplementary analysis, we performed the same univariable and multivariable Cox proportional hazards analyses for an earlier cohort of patients who received a deceased donor transplant from 1/1/1995-12/3/2014. As in our primary analysis, we used transplant program as the random effects term and controlled for all measured donor and recipient characteristics and transplant logistics.

Results were considered statistically significant with a p-value less than 0.05. Prior to conducting this analysis, we estimated that with a sample size of 35,264 recipients, we would have an 80% power to detect a difference of 2.0% in the hazard ratio for graft loss associated with DCD compared with DBD status for the primary analysis. We performed comparative statistics using JMP-Pro Version 13.0.1 (SAS Institute, Inc., Cary, NC, USA) and Cox proportional hazards models using R version 3.5.1 and the coxme 2.2--10 package.

Results {#sec011}
=======

Cohort characteristics {#sec012}
----------------------

Our cohort consisted of 27,494 DBD kidney recipients and 7,770 DCD kidney recipients who received a kidney transplant in the US between 12/4/2014 and 6/30/2018. Recipients had a median follow up of 1.92 years (IQR 1.08--2.83). Compared with DBD donors, DCD donors were less frequently in the youngest and oldest age groups, and more often white ([Table 1](#pone.0233610.t001){ref-type="table"}). The cause of death for DCD donors was more commonly anoxia or an unspecified other cause compared with DBD donors who more often died from a CVA or from head trauma. Serum creatinine was, on average, lower among DCD donors compared with DBD donors, and DCD donors less often had a positive HCV status. DCD donors more often had a history of smoking, but less often had a history of diabetes or hypertension compared with DBD donors. DCD recipients were more often white and more frequently had a low PRA. DCD grafts were more often preserved by machine perfusion before transplantation, had a longer CIT, and more often came from local sharing networks compared with DBD grafts.

Outcomes {#sec013}
--------

Overall, the hazard ratio for graft loss associated with DCD status compared with DBD status was 0.96 (95% confidence interval (CI) 0.87--1.05) in univariable analysis and 1.03 (95% CI 0.94--1.13) in multivariable analysis ([Table 2](#pone.0233610.t002){ref-type="table"}). The hazard ratio for death-censored graft loss associated with DCD status compared with DBD status was 0.97 (95% CI 0.91--1.06) in univariable analysis and 1.05 (95% CI 0.99--1.11) in multivariable analysis. In sensitivity analyses, we found no significant interaction effects for any variables included in the model and no difference in results after excluding imputed CIT values.

10.1371/journal.pone.0233610.t002

###### Association of DCD donor status with kidney graft loss.

![](pone.0233610.t002){#pone.0233610.t002g}

                                        HR (95% CI)         p-value
  ------------------------------------- ------------------- ---------
  **Contemporary cohort: 2014--2018**                       
  Graft loss                                                
  Univariable analysis                  0.96 (0.87--1.05)   0.35
  Multivariable analysis                1.03 (0.95--1.13)   0.57
  Death-censored graft loss                                 
  Univariable analysis                  0.97 (0.91--1.06)   0.66
  Multivariable analysis                1.05 (0.99--1.11)   0.42
  **Early cohort: 1995--2014**                              
  Graft loss                                                
  Univariable analysis                  0.93 (0.91--0.96)   0.54
  Multivariable analysis                1.01 (0.98--1.04)   0.77
  Death-censored graft loss                                 
  Univariable analysis                  0.99 (0.96--1.03)   0.88
  Multivariable analysis                1.11 (1.07--1.15)   0.003

Cox proportional hazard model with mixed effects using \'transplant program\' as the random variable. Multivariable analyses are controlled for all measured donor variables, all measured recipient characteristics, and transplant logistic.

Abbreviations: DCD; Donor after circulatory death; HR, hazard Ratio; CI, confidence interval.

For the earlier cohort of patients who received a deceased donor kidney transplant from 1995--2014, the hazard ratio for graft loss associated with DCD status compared with DBD status was 0.93 (95% CI 0.91--0.96) in univariable analysis and 1.01 (95% CI 0.98--1.04) in multivariable analysis. The hazard ratio for death-censored graft loss was 0.99 (0.96--1.03) in univariable and 1.11 (1.07--1.15) in multivariable analysis.

Among 7,770 DCD donor kidneys transplanted from 2014--2018, 961 (12.4%) had a KDPI of 0--20%, 6248 (80.4%) had a KDPI of 21--85%, and 561 (7.2%) had a KDPI of 86--100% ([Table 3](#pone.0233610.t003){ref-type="table"}). After modifying the published KDRI model by excluding the coefficient for DCD status \[[@pone.0233610.ref024]\], we calculated that 2,219 (28.6%) members of our cohort would have had a KDPI of 0--20%, 5,445 (70.1%) would have had a KDPI of 21--85%, and 106 (1.4%) would have had a KDPI of 86--100% if the DCD status coefficient were not included in the KDRI model.

10.1371/journal.pone.0233610.t003

###### KDPI of DCD kidneys transplanted from 2014--2018 using KDPI models with and without a DCD term.

![](pone.0233610.t003){#pone.0233610.t003g}

                 KDPI model including DCD coefficient (current model)   KDPI model excluding DCD coefficient
  -------------- ------------------------------------------------------ --------------------------------------
      0--20%     961 (12.4)                                             2,219 (28.6)
      21--85%    6,248 (80.4)                                           5,445 (70.1)
      86--100%   561 (7.2)                                              106 (1.4)

Abbreviations: DCD, donor after circulatory death; KDPI, kidney donor profile index.

Discussion {#sec014}
==========

For a national cohort of adults in the US who received a deceased donor kidney transplant between 2014 and 2018, we did not find a difference in the likelihood of experiencing all-cause or death-censored graft loss for DCD kidney recipients compared with DBD kidney recipients, even after adjustment for measured differences in donor and recipient characteristics and transplant logistics.

In the context of ongoing organ shortage, the kidney transplant community has striven to innovate and maximize use of available donor grafts while also respecting an obligation to preserve excellent outcomes for individual patients. Recognizing the tension between these two goals, there has been caution in accepting DCD kidneys in light of early studies showing relatively poor outcomes compared with DBD kidneys \[[@pone.0233610.ref010],[@pone.0233610.ref012]--[@pone.0233610.ref014],[@pone.0233610.ref022],[@pone.0233610.ref023]\]. However, for a contemporary cohort of deceased donor kidney transplant recipients, we did not find a difference in risk of graft loss between DCD and DBD kidney recipients. These findings call into question the assumption that these two types of donor kidneys differ in quality. Two major distinctions between our analysis and existing reports may contribute to these differing results. First, we used a novel approach to modeling the likelihood of graft loss that accounted for possible clustering of unmeasured differences in baseline hazard functions between transplant programs by using a Cox proportional hazards model with mixed effects \[[@pone.0233610.ref025]\]. Differences in experience, technique, and practice patterns between transplant centers may meaningfully contribute to estimates of outcomes for DCD versus DBD grafts. This multilevel approach to survival analysis may prove valuable for future analyses modeling other kidney transplant outcomes. Second, we studied a more contemporary cohort of transplant recipients compared with prior reports. Our supplementary analysis offered mixed signals about whether the risk of graft loss associated with DCD compared with DBD status might differ between early and more recent time periods. Specifically, our multivariable analysis for an earlier cohort of transplant recipients did not show a difference between DCD and DBD recipients for the hazard of all-cause graft loss, but we did detect a greater hazard for death-censored graft loss associated with DCD status for this earlier cohort. This signal of improving DCD graft survival compared with DBD graft survival may reflect the great strides that the transplant community has made over the last decades in effective use of DCD kidneys including better selection of potential donors \[[@pone.0233610.ref016],[@pone.0233610.ref018],[@pone.0233610.ref026]--[@pone.0233610.ref028]\], standardized surgical technique \[[@pone.0233610.ref008]\], and improved preservation of kidney grafts \[[@pone.0233610.ref029],[@pone.0233610.ref030]\].

The inclusion of DCD status as a marker of graft quality in the KDPI may have a substantial impact on distribution and discard patterns of deceased donor kidneys in the US. The current US kidney allocation system relies on the KDPI to support a longevity-matching strategy whereby the highest-quality grafts (KDPI less than 20%) are allocated to patients with the longest post-transplant estimated survival \[[@pone.0233610.ref031]\]. At the other end of the kidney quality spectrum, discard rates for kidneys with a KDPI greater than 85% have substantially increased since implementation of the new kidney allocation system \[[@pone.0233610.ref001]\]. This might be attributed in part to what Bae et al. describe as a "labeling effect" that can bias transplant teams toward discard of high-KDPI kidneys \[[@pone.0233610.ref032]\]. Our supplementary analysis suggests that inclusion of DCD status in the KDPI may materially impact how these donor kidneys are categorized. For example, a kidney from a 65-year-old donor with no pertinent medical history who died from head trauma would be assigned a KDPI of 85% if the donor died by DCD criteria, and 74% if the donor died by DBD criteria \[[@pone.0233610.ref033]\]. Similarly, a kidney from a 25-year-old donor with no pertinent medical history who died from head trauma would be assigned a KDPI of 31% if the donor died by DCD criteria and 17% if the donor died by DBD criteria. After excluding the DCD term from the KDRI model, 1,258 (16%) DCD kidneys in our cohort were re-classified from a KDPI of 20%-85% to ≤20%, and 455 (6%) DCD kidneys in our cohort were re-classified from a KDPI of \>85% to ≤85%. While we intend this analysis only as an illustrative approximation, it suggests that there may be a sizable number of high-quality DCD kidneys more effectively allocated to recipients who have a longer post-transplant estimated survival and that there may be many good-quality DCD kidneys at risk of being discarded. These observations underline the importance of re-evaluating the inclusion of DCD status in the KDPI and signal an opportunity for transplant center teams to identify and utilize potentially valuable DCD kidneys based on their assessment of multiple graft characteristics rather than relying primarily on an aggregate measure of quality.

Limitations {#sec015}
-----------

This study should be interpreted with several limitations in mind. First, because we targeted a contemporary cohort of transplant recipients, the follow-up period is relatively short. Future study may offer insight into patterns in longer-term graft survival and also lend additional power to detect small differences in graft survival. Second, kidney graft quality may be judged by other patient-important outcomes that we are unable to report using this study design (e.g., acute rejection, length of hospital stay, rehospitalizations). However, our findings do align with accumulating observations from other work showing little difference in other outcomes for recipients of DCD compared with DBD grafts in the US and internationally \[[@pone.0233610.ref015]--[@pone.0233610.ref018],[@pone.0233610.ref034]\]. Third, OPTN registry data is limited to outcomes for grafts that were selected for transplant, so these findings may not apply to discarded kidneys. Although we adjusted for all measured characteristics, there may be unmeasured differences between groups. Finally, estimation of the KDPI distribution for our cohort using a KDRI model without the DCD coefficient is intended only as an illustrative approximation. Definitive exclusion of the DCD coefficient might involve adjusting the weight of other coefficients included in the KDRI model.

Conclusions {#sec016}
===========

For a contemporary cohort of deceased donor kidney transplant recipients in the US, we did not observe a significant difference in risk of graft loss for DCD compared with DBD kidney recipients. These findings signal uncertainty about whether DCD status independently contributes to measures of graft quality, and identify an opportunity to promote more effective use of scarce deceased donor kidneys by continuing to update our understanding of markers of graft quality.

The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy of or interpretation by the OPTN or the U.S. Government.

10.1371/journal.pone.0233610.r001
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We will update your Data Availability statement on your behalf to reflect the information you provide.

3\. Thank you for stating the following in the Acknowledgments Section of your manuscript:

The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy of or interpretation by the OPTN or the U.S. Government. Dr. Butler is supported by a training grant from the NIDDK (5T32DK007467-33).

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

The author(s) received no specific funding for this work.

4\. To comply with PLOS ONE submission guidelines, in your Methods section, please provide additional information regarding your statistical analyses. For more information on PLOS ONE\'s expectations for statistical reporting, please see <https://journals.plos.org/plosone/s/submission-guidelines.#loc-statistical-reporting>.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Contemporary patterns in kidney graft survival from donors after circulatory death in the United States

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Very interesting and important study.

Limitations were stated, including the short term follow up and the need for future studies with longer follow up.

1\. Could I ask you please if you have any data on the type of DCD donor eg controlled or uncontrolled or Maastricht category? If yes, did you do

any analysis according to these? If not, please state in the paper that no such data were available.

2\. Do you have any data on delayed graft function to add to the study?

3\. Please add the current practice followed in the US with respect to DCD kidney donation:

a\. How many minutes is the "waiting period" (time after cessation of cardiorespiratory function before death is declared)?

b\. How long do you wait before standing down if there is no cessation of cardiorespiratory function? Does this practice very between US centers?

Thank you.

Reviewer \#2: This paper describes the association of DCD versus DBD donor status with all cause graft loss after kidney transplantation in a recent US-cohort of transplants performed between April 2014 and September 2017. The authors found no association of DCD status with graft loss.

As many transplant professionals perceive DCD kidneys as inferior and the KDRI is negatively impacted by the DCD donor status this paper has a potentially important message for the acceptance of offered kidneys and allocation policy making. The paper confirms recent papers in outcomes in other countries showing similar outcomes in DCD transplantation as compared to DBD transplantation. Overall the central message is clear and relevant. I do feel that somewhat more effort could have been made to corroborate the findings.

Some comments:

\- The median follow up in the study is below one year, thus effects of donor status on longer term outcome may be missed. Follow up is short due to the study design in which the authors aim to analyse a recent cohort. As it has been suggested that DCD donor status negatively impacts early outcome and this is compensated by improved long term outcome, the short term outcome described in this study is probably highly relevant. However, as the authors explain their findings by improved management in DCD transplantation, it may be helpful to actually demonstrate that this short term outcome has improved compared to earlier cohorts.

\- Unfortunately data on other short term outcomes such as delayed graft function or primary non function are not given. Insight into these parameters would be helpful to explain the findings of the study. Again a comparison with earlier cohorts would make the findings more robust.

\- While all cause graft loss as given in the study is the outcome of primary interest, a separate analysis of death censored graft survival may give some additional insight into changing patterns over time.

Minor points:

\- A recent study on the Dutch DCD experience confirming the equivalence of graft survival in DCD and DBD kidney transplantation would seem a useful reference. (Schaapherder et al. EClinicalMedicine. 2018 Oct 9;4-5:25-31)

\- The following is stated in the introduction: "A requisite two to five-minute "waiting period" after cessation of cardiorespiratory function and before death is declared can cause systemic hypotension.." "Can cause systemic hypotension" is a somewhat awkward description of the risks after after cessation of circulation.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Nicos Kessaris

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0233610.r002

Author response to Decision Letter 0

4 Mar 2020

Editorial Staff:

i\) We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

\* In your revised cover letter, please address the following prompts:

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

Data used in this study is managed by the Scientific Registry of Transplant Recipients. It is publicly available upon request at: <https://www.srtr.org/requesting-srtr-data/data-requests/>

c\) We will update your Data Availability statement on your behalf to reflect the information you provide.

ii\) Thank you for stating the following in the Acknowledgments Section of your manuscript:

The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy of or interpretation by the OPTN or the U.S. Government. Dr. Butler is supported by a training grant from the NIDDK (5T32DK007467-33).

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

\* Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

The author(s) received no specific funding for this work.

We have removed any reference to funding from the manuscript. The updated funding statement should read:

Dr. Butler is supported by a training grant from the NIDDK (5T32DK007467-33).

2\. Please remove your figures/ from within your manuscript file, leaving only the individual TIFF/EPS image files. These will be automatically included in the reviewer's PDF

This has been corrected.

Academic Editor:

This MS is of interest to the tx community, showing equivalent survival of DCD vs DBD kidney transplantation.

Reviewers do highlight some issues that would need to be addressed in detail. Especially, some additional outcomes are missing that would be important to include.

Below, we include a point-by-point response to reviewer comments including regarding alternative outcomes.

Reviewer \#1:

1\. Could I ask you please if you have any data on the type of DCD donor eg controlled or uncontrolled or Maastricht category? If yes, did you do any analysis according to these? If not, please state in the paper that no such data were available.

We have now clarified that all donations in the US are controlled (Maastricht category III). \[Introduction, paragraph 2\]

2\. Do you have any data on delayed graft function to add to the study?

We agree that delayed graft function would be a valuable outcome. However, because definitions of delayed graft function vary between transplant centers and reporting is heterogenous, we did not believe that the current dataset offered sufficiently robust information to include this outcome for the current analysis.

3\. Please add the current practice followed in the US with respect to DCD kidney donation:

a\. How many minutes is the "waiting period" (time after cessation of cardiorespiratory function before death is declared)?

We now describe the 2-5 minute "waiting period" before declaration of death for DCD donors. \[Introduction, paragraph 2\]

b\. How long do you wait before standing down if there is no cessation of cardiorespiratory function? Does this practice very between US centers?

We now include information about what is typically a 1-hour cut-off time after withdrawal of life-supporting treatment in the US. \[Introduction, paragraph 2\]

Reviewer \#2:

This paper describes the association of DCD versus DBD donor status with all cause graft loss after kidney transplantation in a recent US-cohort of transplants performed between April 2014 and September 2017. The authors found no association of DCD status with graft loss.

As many transplant professionals perceive DCD kidneys as inferior and the KDRI is negatively impacted by the DCD donor status this paper has a potentially important message for the acceptance of offered kidneys and allocation policy making. The paper confirms recent papers in outcomes in other countries showing similar outcomes in DCD transplantation as compared to DBD transplantation. Overall the central message is clear and relevant. I do feel that somewhat more effort could have been made to corroborate the findings.

Some comments:

\- The median follow up in the study is below one year, thus effects of donor status on longer term outcome may be missed. Follow up is short due to the study design in which the authors aim to analyse a recent cohort. As it has been suggested that DCD donor status negatively impacts early outcome and this is compensated by improved long term outcome, the short term outcome described in this study is probably highly relevant. However, as the authors explain their findings by improved management in DCD transplantation, it may be helpful to actually demonstrate that this short term outcome has improved compared to earlier cohorts.

We have now extended the follow-up period for our cohort as updated data was available in the time since initial submission. We also include a secondary analysis for an earlier cohort in order to support more direct comparisons across eras. We chose to define this earlier cohort with a longer follow-up time to assess whether our choice of model (a mixed cox proportional hazard model) may also contribute to differences that we see between our analyses and prior studies.

\- Unfortunately data on other short term outcomes such as delayed graft function or primary non function are not given. Insight into these parameters would be helpful to explain the findings of the study. Again a comparison with earlier cohorts would make the findings more robust.

As noted in response to Reviewer \#1's comments above, we agree that delayed graft function is an outcome of general interest. We decided not to pursue this outcome because we did not find reports in our dataset to be sufficiently consistent to support validity.

\- While all cause graft loss as given in the study is the outcome of primary interest, a separate analysis of death censored graft survival may give some additional insight into changing patterns over time.

We decided to not include death-censored graft loss for this analysis because we find it difficult to reliably disentangle what is often a complex relationship between death and deteriorating graft function. For example, failing graft function may nonetheless lead to recipient death before frank graft failure can be reported. We believe that this approach aligns with existing work such as in Rao et al. and Zhong et al.

Minor points:

\- A recent study on the Dutch DCD experience confirming the equivalence of graft survival in DCD and DBD kidney transplantation would seem a useful reference. (Schaapherder et al. EClinicalMedicine. 2018 Oct 9;4-5:25-31)

We appreciate the suggestion and now reference this study. \[Discussion, paragraph 2\]

\- The following is stated in the introduction: "A requisite two to five-minute "waiting period" after cessation of cardiorespiratory function and before death is declared can cause systemic hypotension.." "Can cause systemic hypotension" is a somewhat awkward description of the risks after after cessation of circulation.

We have clarified this language. \[Introduction, paragraph 2\]

###### 

Submitted filename: DCD_response to reviewers_1.28.20.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0233610.r003
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Frank JMF Dor

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

2 Apr 2020

PONE-D-19-29374R1

Contemporary patterns in kidney graft survival from donors after circulatory death in the United States

PLOS ONE

Dear Dr. Sibulesky,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR:

Thank you for making an effort to address the issues pointed out by the reviewers. However, I agree with reviewer 2 that a few remaining issues should be dealt with appropriately. I hope you can take those points seriously and follow them through in the discussion and conclusions of a revised MS. I would like to emphasize that the points brought up by reviewer 2 are crucial and the revised MS will only be taken into consideration for publication if the revisions are satisfactory. I think your study can really contribute to the field if these extremely important concerns can be ironed out. Looking forward to your revised MS.

==============================

We would appreciate receiving your revised manuscript by May 17 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Frank JMF Dor, M.D., Ph.D., FEBS, FRCS

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Thank you for addressing all the questions and comments made previously and for providing the extra US data for the period between 1995 and 2014. It would be interesting to repeat the study in a few years time and compare the outcomes of DBD and DCD grafts at 3 and 5 years post transplant.

Reviewer \#2: I do not feel that the reviewers comments have been adequately addressed:

\- The authors now show that with their methodology the multivariate analysis does not show a survival disadvantage in the historical cohort. This is a direct contradiction with the central message of the paper and has not lead to any adaptations in the discussion or the conclusions that still ponder on improved outcome. Either DCD transplantation outcome was not poorer in the past or the applied analysis is not able to detect this.

\- The authors dismiss the suggestion to include death censored graft loss by citing two papers on the development of a risk index and making the point that death censored graft loss misses patient death due to poor graft function as an outcome. While death censored graft loss of course had its shortcomings the same holds true for overall composite graft loss. I do not think that papers aiming to develop a risk index for patient survival after transplantation are adequate references to justify leaving out death censored graft survival in a paper on understanding changing outcome patterns in DCD transplantation.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Nicos Kessaris

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0233610.r004

Author response to Decision Letter 1

13 Apr 2020

Response to editorial and reviewer comments:

Academic editor:

Thank you for making an effort to address the issues pointed out by the reviewers. However, I agree with reviewer 2 that a few remaining issues should be dealt with appropriately. I hope you can take those points seriously and follow them through in the discussion and conclusions of a revised MS. I would like to emphasize that the points brought up by reviewer 2 are crucial and the revised MS will only be taken into consideration for publication if the revisions are satisfactory. I think your study can really contribute to the field if these extremely important concerns can be ironed out. Looking forward to your revised MS.

As detailed below, we added death-censored graft loss as a secondary outcome and made major changes to the discussion to reflect the reviewer' comments.

Reviewer \#1: Thank you for addressing all the questions and comments made previously and for providing the extra US data for the period between 1995 and 2014. It would be interesting to repeat the study in a few years time and compare the outcomes of DBD and DCD grafts at 3 and 5 years post transplant.

We agree with suggestions for future studies and thank the reviewer for their review.

Reviewer \#2:

\- The authors now show that with their methodology the multivariate analysis does not show a survival disadvantage in the historical cohort. This is a direct contradiction with the central message of the paper and has not lead to any adaptations in the discussion or the conclusions that still ponder on improved outcome. Either DCD transplantation outcome was not poorer in the past or the applied analysis is not able to detect this.

We fully appreciate the reviewer's critique and have made major changes to re-focus the discussion around the novel methodology (Cox proportional hazard model with mixed effects using transplant center as the random effect term) that we believe contributes to differences in our findings compared with earlier reports. We have also removed a figure quantifying the changing volume of DCD kidney transplants in the US to better focus discussion on this first point of distinction between our study and earlier work. However, in performing the suggested analyses for death-censored graft loss on the earlier cohort, we now report higher risk of death-censored graft loss for DCD kidneys in this earlier cohort. In light of this new finding, we retain a much attenuated discussion of possible improvements in practice around DCD transplant that could have contributed to different findings for early and contemporary cohorts of deceased donor transplant recipients.

\- The authors dismiss the suggestion to include death censored graft loss by citing two papers on the development of a risk index and making the point that death censored graft loss misses patient death due to poor graft function as an outcome. While death censored graft loss of course had its shortcomings the same holds true for overall composite graft loss. I do not think that papers aiming to develop a risk index for patient survival after transplantation are adequate references to justify leaving out death censored graft survival in a paper on understanding changing outcome patterns in DCD transplantation.

We take the reviewers point, and have added death-censored graft loss as a secondary outcome. For the primary (contemporary) cohort of transplant recipients, findings are similar for the outcomes of all-cause and death-censored graft loss.

10.1371/journal.pone.0233610.r005
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, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

29 Apr 2020

PONE-D-19-29374R2

Contemporary patterns in kidney graft survival from donors after circulatory death in the United States

PLOS ONE

Dear Dr. Sibulesky,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that a minor revision would still be required. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Thank you for making the changes to your paper as requested. The MS has significantly improved thanks to this. I would like to propose to add reviewer 1\'s suggestion to the discussion. Provisionally accepted pending the minor revision.

We would appreciate receiving your revised manuscript by Jun 13 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Frank JMF Dor, M.D., Ph.D., FEBS, FRCS

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Thank you for making the changes suggested by the second reviewer. The large sample of DBD and DCD donors as well as the interesting outcomes, contribute hugely to the value of this paper.

After reading your publication, members of the transplant community will be questioning whether they should be accepting more DCD kidneys. Can I ask you to add your thoughts on this issue and how you may have changed your practice following these outcomes please?

Reviewer \#2: I want to thank the authors for the latest changes to the paper. The current version has a clear and important message. I have no further comments.
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